文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

体外二氧化碳清除治疗慢性阻塞性肺疾病急性加重(ORION):随机对照试验研究方案

Extracorporeal carbon dioxide removal for treatment of exacerbated chronic obstructive pulmonary disease (ORION): study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2021-10-19

本研究为多中心随机对照非盲临床试验,计划纳入284例因COPD急性加重导致高碳酸性呼吸衰竭、需要无创通气支持的的患者,比较ECCO2R联合NIV与标准NIV的疗效。主要结局为28天无事件生存率,事件包括无长期机械通气、严重低氧血症、感染性休克和COPD急性加重再发。研究旨在评估ECCO2R能否避免插管并改善预后。

要点

  • 研究纳入需NIV的COPD高碳酸性呼吸衰竭患者,随机比较ECCO2R与标准治疗。
  • 主要复合结局为28天无事件生存,包括避免长期机械通气、严重低氧、休克和再加重。
  • 该试验旨在回答ECCO2R能否替代有创通气并降低相关风险。

核心结论

  • ECCO2R用于COPD急性加重的疗效与安全性证据不足,需随机对照试验验证。
  • 本试验旨在评估ECCO2R能否避免有创通气并改善28天无事件生存。

研究设计与样本

  • 多中心、随机、对照、非盲临床试验,计划纳入284例患者(每组142例)。
  • 研究对象为COPD急性加重导致急性高碳酸性呼吸衰竭、需要无创通气支持的患者。
  • 主要结局为28天无事件生存,复合事件包括无长期机械通气、严重低氧血症、感染性休克和COPD急性加重再发。
  • 次要结局包括气管插管和气管切开发生率、ICU和住院时间及90天死亡率。

临床怎么用

  • 对于COPD急性加重高碳酸性呼吸衰竭且NIV治疗不佳的患者,ECCO2R可能作为避免有创通气的选择,但需等待试验结果。
  • 临床决策需权衡有创通气的风险与ECCO2R可能的不良事件。

局限性

  • 研究方案阶段,尚无疗效和安全性结果。
  • 非盲设计可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypercapnic exacerbations are severe complications of chronic obstructive pulmonary disease (COPD), characterized by negative impact on prognosis, quality of life and healthcare costs. The present standard of care for acute exacerbations of COPD is non-invasive ventilation; when it fails, the use of invasive mechanical ventilation is inevitable, but is associated with extremely poor prognosis. Extracorporeal circuits designed to remove CO2 (ECCO2R) may enhance the efficacy of NIV to remove CO2 and avoid the worsening of respiratory acidosis, which inevitably leads to failure of non-invasive ventilation. Although the use of ECCO2R for acute exacerbations of COPD is steadily increasing, solid evidence on its efficacy and safety is scarce, thus the need for a randomized controlled trial. METHODS: multicenter randomized controlled unblinded clinical trial including 284 (142 per arm) patients with acute hypercapnic respiratory failure caused by exacerbation of COPD, requiring respiratory support with NIV. The primary outcome is event free survival at 28 days, a composite outcome defined by survival in absence of prolonged mechanical ventilation, severe hypoxemia, septic shock and second episode of COPD exacerbation. Secondary outcomes are incidence of endotracheal intubation and tracheostomy, intensive care and hospital length-of-stay and 90-day mortality. DISCUSSION: Acute exacerbations of COPD represent a significant burden in terms of prognosis, quality of life and healthcare costs. Lack definite evidence despite increasing use of ECCO2R justifies a randomized trial to evaluate whether patients with acute hypercapnic acidosis not responsive to NIV should undergo invasive mechanical ventilation (with all serious related risks) or be treated with ECCO2R to avoid invasive ventilation but be exposed to possible adverse events of ECCO2R. Owing to its pragmatic nature, sample size and composite primary outcome, this trial aims at providing valuable answers to relevant questions for clinical treatment of acute exacerbations of COPD. TRIAL REGISTRATION: ClinicalTrials.gov , NCT04582799 . Registered 12 October 2020, .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Tonetti T, Pisani L, Cavalli I, et al. Extracorporeal carbon dioxide removal for treatment of exacerbated chronic obstructive pulmonary disease (ORION): study protocol for a randomised controlled trial. Trials. 2021. PMID: 34666820. doi:10.1186/s13063-021-05692-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。